$2.02
+0.10 (+5.21%)
Open$1.97
Previous Close$1.92
Day High$2.04
Day Low$1.95
52W High$23.03
52W Low$10.85
Volume—
Avg Volume292.0K
Market Cap143.48M
P/E Ratio42.85
EPS$0.37
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+720.3% upside
Current
$2.02
$2.02
Target
$16.57
$16.57
$14.06
$16.57 avg
$23.26
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 19.33M | 18.18M | 17.68M |
| Net Income | -947,103 | -802,247 | -886,084 |
| Profit Margin | -4.9% | -4.4% | -5.0% |
| EBITDA | -1,287,077 | -1,124,832 | -1,061,399 |
| Free Cash Flow | -739,760 | -479,993 | -441,081 |
| Rev Growth | +21.0% | +13.7% | -3.4% |
| Debt/Equity | 0.36 | 0.44 | 0.33 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |